Showing
5 changed files
with
1 additions
and
696 deletions
| 1 | -# missing word embeddings: | ||
| 2 | -29c | ||
| 3 | -14 | ||
| 4 | -31 | ||
| 5 | -26a | ||
| 6 | -beta1 | ||
| 7 | -486 | ||
| 8 | -profibrotic | ||
| 9 | -92a | ||
| 10 | -29a | ||
| 11 | -matricellular | ||
| 12 | -155 | ||
| 13 | -13 | ||
| 14 | -b1 | ||
| 15 | -etiopathology | ||
| 16 | -nexin | ||
| 17 | -avb6 | ||
| 18 | -21 | ||
| 19 | -19 | ||
| 20 | -acetylglucosaminidase | ||
| 21 | -326 | ||
| 22 | -dermatan | ||
| 23 | -1b | ||
| 24 | -p38 | ||
| 25 | -47 | ||
| 26 | -68 | ||
| 27 | -3p | ||
| 28 | -dedifferentiating | ||
| 29 | -alpha3beta1 | ||
| 30 | -chymase | ||
| 31 | -2alpha | ||
| 32 | -90 | ||
| 33 | -7d | ||
| 34 | -5100 | ||
| 35 | -18a | ||
| 36 | -1a | ||
| 37 | -alpha3 | ||
| 38 | -150 | ||
| 39 | -1343 | ||
| 40 | -140 | ||
| 41 | -541 | ||
| 42 | -fibrogenesis | ||
| 43 | -221 | ||
| 44 | -mitophagy | ||
| 45 | -b4 | ||
| 46 | -p63 | ||
| 47 | -10 | ||
| 48 | -5p | ||
| 49 | -haptotactic | ||
| 50 | -nonkinase | ||
| 51 | -farnesoid | ||
| 52 | -lymphopoietin | ||
| 53 | -7a | ||
| 54 | -18 | ||
| 55 | -338 | ||
| 56 | -1beta | ||
| 57 | -424 | ||
| 58 | -199a | ||
| 59 | -154 | ||
| 60 | -smad2 | ||
| 61 | -17 | ||
| 62 | -185 | ||
| 63 | -bronchoalveolar | ||
| 64 | -101 | ||
| 65 | -profibrogenic | ||
| 66 | -153 | ||
| 67 | -gambogic | ||
| 68 | -ubiquitinating | ||
| 69 | -p110y | ||
| 70 | -200 | ||
| 71 | -323a | ||
| 72 | -196a | ||
| 73 | -dysregulates | ||
| 74 | -fibrogenic | ||
| 75 | -salvianolic | ||
| 76 | -# missing MI weights: | ||
| 77 | -Tumor | ||
| 78 | -sTNFR | ||
| 79 | -Compromised | ||
| 80 | -Modulating | ||
| 81 | -Renin | ||
| 82 | -Invasive | ||
| 83 | -Cytokine | ||
| 84 | -D1 | ||
| 85 | -C3aR | ||
| 86 | -Prostaglandin | ||
| 87 | -Diagnostic | ||
| 88 | -HLA | ||
| 89 | -Interstitial | ||
| 90 | -Transforming | ||
| 91 | -Phenotypes | ||
| 92 | -Up | ||
| 93 | -Clinical | ||
| 94 | -TGFb | ||
| 95 | -Interplay | ||
| 96 | -Animal | ||
| 97 | -Decoction | ||
| 98 | -Foxp3high | ||
| 99 | -Leucine | ||
| 100 | -CCL2 | ||
| 101 | -SDKP | ||
| 102 | -IL | ||
| 103 | -Correct | ||
| 104 | -Elk1 | ||
| 105 | -Participation | ||
| 106 | -Azithromycin | ||
| 107 | -Amplification | ||
| 108 | -1A | ||
| 109 | -Endothelin | ||
| 110 | -Kinase | ||
| 111 | -Possible | ||
| 112 | -Associated | ||
| 113 | -MicroRNA | ||
| 114 | -sL1 | ||
| 115 | -Action | ||
| 116 | -For | ||
| 117 | -Development | ||
| 118 | -Establishment | ||
| 119 | -Extracellular | ||
| 120 | -Epstein | ||
| 121 | -MUM | ||
| 122 | -Serine | ||
| 123 | -Interactions | ||
| 124 | -Macrophage | ||
| 125 | -Pseudomonas | ||
| 126 | -Cytokines | ||
| 127 | -IGFBP | ||
| 128 | -Calu | ||
| 129 | -PI3K | ||
| 130 | -B4 | ||
| 131 | -Chinese | ||
| 132 | -Cigarette | ||
| 133 | -BALF | ||
| 134 | -NK | ||
| 135 | -alphaEbeta7 | ||
| 136 | -microRNAs | ||
| 137 | -Gene | ||
| 138 | -True | ||
| 139 | -Pneumonia | ||
| 140 | -CUX1 | ||
| 141 | -miRNA | ||
| 142 | -Ubiquitin | ||
| 143 | -Wnt | ||
| 144 | -CDCP1 | ||
| 145 | -Barr | ||
| 146 | -ORP150 | ||
| 147 | -Curcumin | ||
| 148 | -aB | ||
| 149 | -Myofibroblast | ||
| 150 | -JNK | ||
| 151 | -Aortic | ||
| 152 | -L5 | ||
| 153 | -Hsp90 | ||
| 154 | -Smoke | ||
| 155 | -IFN | ||
| 156 | -Reactive | ||
| 157 | -Significance | ||
| 158 | -aVb6 | ||
| 159 | -Th2 | ||
| 160 | -Constitutive | ||
| 161 | -Melatonin | ||
| 162 | -Mediates | ||
| 163 | -AP | ||
| 164 | -Lindau | ||
| 165 | -ALK5 | ||
| 166 | -AKT2 | ||
| 167 | -EMT | ||
| 168 | -Reversion | ||
| 169 | -Patients | ||
| 170 | -Solution | ||
| 171 | -Focal | ||
| 172 | -Immunoglobulin | ||
| 173 | -RhoA | ||
| 174 | -Neutrophil | ||
| 175 | -BMPR2 | ||
| 176 | -CXCL9 | ||
| 177 | -Lower | ||
| 178 | -Olodaterol | ||
| 179 | -Lavage | ||
| 180 | -Induces | ||
| 181 | -Induced | ||
| 182 | -Beyond | ||
| 183 | -MMP | ||
| 184 | -Fstl1 | ||
| 185 | -cAMP | ||
| 186 | -Aging | ||
| 187 | -SPARC | ||
| 188 | -Activity | ||
| 189 | -ECM | ||
| 190 | -Human | ||
| 191 | -Fibrotic | ||
| 192 | -Repression | ||
| 193 | -Prostatic | ||
| 194 | -NOX4 | ||
| 195 | -Against | ||
| 196 | -Discovery | ||
| 197 | -Resveratrol | ||
| 198 | -Interleukin | ||
| 199 | -Deleted | ||
| 200 | -Differentiation | ||
| 201 | -Spiruchostatin | ||
| 202 | -Insulin | ||
| 203 | -PXS64 | ||
| 204 | -MCTC | ||
| 205 | -HP | ||
| 206 | -Triptolide | ||
| 207 | -Values | ||
| 208 | -Differential | ||
| 209 | -Lysyl | ||
| 210 | -FGF | ||
| 211 | -Promote | ||
| 212 | -Yin | ||
| 213 | -Tissue | ||
| 214 | -BMP | ||
| 215 | -CAM | ||
| 216 | -Discoidin | ||
| 217 | -Overproduction | ||
| 218 | -Wilms | ||
| 219 | -Regulates | ||
| 220 | -Reduced | ||
| 221 | -Mesenchymal | ||
| 222 | -Inflammation | ||
| 223 | -PINK1 | ||
| 224 | -Release | ||
| 225 | -E2 | ||
| 226 | -CD44V6 | ||
| 227 | -TGFbeta1 | ||
| 228 | -Rg1 | ||
| 229 | -H441 | ||
| 230 | -kDa | ||
| 231 | -M2 | ||
| 232 | -Expression | ||
| 233 | -Data | ||
| 234 | -Contribution | ||
| 235 | -Negative | ||
| 236 | -Nintedanib | ||
| 237 | -Pulmonary | ||
| 238 | -Emphysema | ||
| 239 | -Intrinsic | ||
| 240 | -17A | ||
| 241 | -Marks | ||
| 242 | -26S | ||
| 243 | -RXFP1 | ||
| 244 | -Neovessel | ||
| 245 | -Genetic | ||
| 246 | -Protective | ||
| 247 | -Tensin | ||
| 248 | -Inducer | ||
| 249 | -Like | ||
| 250 | -Determining | ||
| 251 | -Increased | ||
| 252 | -Microsatellite | ||
| 253 | -Sphingosine | ||
| 254 | -TRPV4 | ||
| 255 | -Club | ||
| 256 | -Methylation | ||
| 257 | -Phenoconversion | ||
| 258 | -Serpin | ||
| 259 | -Activated | ||
| 260 | -Muc5ac | ||
| 261 | -MyD88 | ||
| 262 | -Glucagon | ||
| 263 | -IPF | ||
| 264 | -SIRT6 | ||
| 265 | -Rapamycin | ||
| 266 | -Essential | ||
| 267 | -TNFalpha | ||
| 268 | -Corilagin | ||
| 269 | -Sorafenib | ||
| 270 | -Epithelial | ||
| 271 | -T869C | ||
| 272 | -Induction | ||
| 273 | -Long | ||
| 274 | -Wt1 | ||
| 275 | -Molecules | ||
| 276 | -TGFBR2 | ||
| 277 | -P110 | ||
| 278 | -Nuclear | ||
| 279 | -Old | ||
| 280 | -Targeting | ||
| 281 | -WNT7B | ||
| 282 | -Thy | ||
| 283 | -Potential | ||
| 284 | -TGF | ||
| 285 | -Tubastatin | ||
| 286 | -Semaphorin | ||
| 287 | -Attenuating | ||
| 288 | -Smad | ||
| 289 | -Pigment | ||
| 290 | -Homolog | ||
| 291 | -Binding | ||
| 292 | -microRNA | ||
| 293 | -C57BL | ||
| 294 | -Regulating | ||
| 295 | -Implications | ||
| 296 | -Hydrogen | ||
| 297 | -BARD1 | ||
| 298 | -A549 | ||
| 299 | -Homeostasis | ||
| 300 | -Selectivity | ||
| 301 | -Medical | ||
| 302 | -Model | ||
| 303 | -Cytoskeletal | ||
| 304 | -Differing | ||
| 305 | -BMP3 | ||
| 306 | -Enhances | ||
| 307 | -NADPH | ||
| 308 | -Fibrogenesis | ||
| 309 | -Defect | ||
| 310 | -Two | ||
| 311 | -FAK | ||
| 312 | -RNA | ||
| 313 | -Quantifying | ||
| 314 | -Epigenetic | ||
| 315 | -Profibrotic | ||
| 316 | -Ambroxol | ||
| 317 | -Trigger | ||
| 318 | -Titration | ||
| 319 | -Transcription | ||
| 320 | -Regulation | ||
| 321 | -Mitochondrial | ||
| 322 | -H1N1 | ||
| 323 | -Recent | ||
| 324 | -BMPER | ||
| 325 | -PPARs | ||
| 326 | -VCAM | ||
| 327 | -Microsomal | ||
| 328 | -Hippel | ||
| 329 | -Renshen | ||
| 330 | -Absence | ||
| 331 | -Anchorage | ||
| 332 | -Applying | ||
| 333 | -Free | ||
| 334 | -OSF | ||
| 335 | -PGE | ||
| 336 | -Tannic | ||
| 337 | -Plasminogen | ||
| 338 | -TGFBR | ||
| 339 | -Channel | ||
| 340 | -Age | ||
| 341 | -Cell | ||
| 342 | -Connective | ||
| 343 | -Proteasomal | ||
| 344 | -RAGE | ||
| 345 | -Bach1 | ||
| 346 | -Pirfenidone | ||
| 347 | -Outcomes | ||
| 348 | -GATA | ||
| 349 | -Small | ||
| 350 | -Autoimmunity | ||
| 351 | -III | ||
| 352 | -VEGF | ||
| 353 | -Control | ||
| 354 | -HSP27 | ||
| 355 | -Cartilage | ||
| 356 | -Periostin | ||
| 357 | -Idiopathic | ||
| 358 | -COL1A1 | ||
| 359 | -CBP | ||
| 360 | -Bronchoalveolar | ||
| 361 | -Crosstalk | ||
| 362 | -Amplified | ||
| 363 | -Evidence | ||
| 364 | -Simvastatin | ||
| 365 | -Sphingolipids | ||
| 366 | -Mechanisms | ||
| 367 | -JAK2 | ||
| 368 | -Rats | ||
| 369 | -Mice | ||
| 370 | -Protease | ||
| 371 | -From | ||
| 372 | -LPA1 | ||
| 373 | -Collagen | ||
| 374 | -Carbon | ||
| 375 | -Molecular | ||
| 376 | -Stat3 | ||
| 377 | -Genomewide | ||
| 378 | -Stem | ||
| 379 | -S1P | ||
| 380 | -Novel | ||
| 381 | -EBV | ||
| 382 | -Serum | ||
| 383 | -Abrogation | ||
| 384 | -That | ||
| 385 | -Pingfei | ||
| 386 | -Stromal | ||
| 387 | -Current | ||
| 388 | -Molecule | ||
| 389 | -MAP3K19 | ||
| 390 | -Decisive | ||
| 391 | -Protein | ||
| 392 | -Fluid | ||
| 393 | -HDAC4 | ||
| 394 | -Angiotensin | ||
| 395 | -SOCS1 | ||
| 396 | -Different | ||
| 397 | -Membrane | ||
| 398 | -Domain | ||
| 399 | -Secretory | ||
| 400 | -Signalling | ||
| 401 | -NCI | ||
| 402 | -Bax | ||
| 403 | -ADAM | ||
| 404 | -Are | ||
| 405 | -Beta1 | ||
| 406 | -Activation | ||
| 407 | -Problem | ||
| 408 | -Prognostic | ||
| 409 | -II | ||
| 410 | -Sputum | ||
| 411 | -Phosphatase | ||
| 412 | -Inhibition | ||
| 413 | -Profile | ||
| 414 | -Dogs | ||
| 415 | -HRCT | ||
| 416 | -lncRNA | ||
| 417 | -Storage | ||
| 418 | -Nitrated | ||
| 419 | -Box | ||
| 420 | -Forkhead | ||
| 421 | -CREB | ||
| 422 | -Sirtuin | ||
| 423 | -Cryptogenic | ||
| 424 | -Decreased | ||
| 425 | -Inhibits | ||
| 426 | -Formation | ||
| 427 | -MK2 | ||
| 428 | -Comparison | ||
| 429 | -Mediated | ||
| 430 | -Latent | ||
| 431 | -Recombinant | ||
| 432 | -Microencapsulation | ||
| 433 | -PHGDH | ||
| 434 | -Organizing | ||
| 435 | -Dysfunction | ||
| 436 | -Way | ||
| 437 | -Using | ||
| 438 | -Peripheral | ||
| 439 | -Markers | ||
| 440 | -MiR | ||
| 441 | -Anti | ||
| 442 | -Studies | ||
| 443 | -May | ||
| 444 | -Significant | ||
| 445 | -Morphogenic | ||
| 446 | -Low | ||
| 447 | -Lactic | ||
| 448 | -Overexpression | ||
| 449 | -Protects | ||
| 450 | -Arsenic | ||
| 451 | -Caveolin | ||
| 452 | -pH | ||
| 453 | -Inhibit | ||
| 454 | -Proteasome | ||
| 455 | -MicroRNAs | ||
| 456 | -Toll | ||
| 457 | -Herpes | ||
| 458 | -CTGF | ||
| 459 | -Normal | ||
| 460 | -Defective | ||
| 461 | -CD44 | ||
| 462 | -Large | ||
| 463 | -Ligands | ||
| 464 | -Axis | ||
| 465 | -NH2 | ||
| 466 | -Progression | ||
| 467 | -Smad3 | ||
| 468 | -Phenotype | ||
| 469 | -Ets | ||
| 470 | -Identification | ||
| 471 | -kB | ||
| 472 | -Role | ||
| 473 | -Relation | ||
| 474 | -Mode | ||
| 475 | -Developmental | ||
| 476 | -Fibrosis | ||
| 477 | -Stanniocalcin | ||
| 478 | -WNT10A | ||
| 479 | -Integrated | ||
| 480 | -Syndecan | ||
| 481 | -Metalloproteinase | ||
| 482 | -TOB2 | ||
| 483 | -USP11 | ||
| 484 | -WISP1 | ||
| 485 | -Dysregulated | ||
| 486 | -Th17 | ||
| 487 | -Progressive | ||
| 488 | -Key | ||
| 489 | -Subpleural | ||
| 490 | -Mast | ||
| 491 | -Rho | ||
| 492 | -Growth | ||
| 493 | -Upregulation | ||
| 494 | -Alleviates | ||
| 495 | -Re | ||
| 496 | -Preventive | ||
| 497 | -ITGB6 | ||
| 498 | -Fibroblasts | ||
| 499 | -ATG4B | ||
| 500 | -Comparative | ||
| 501 | -Cthrc1 | ||
| 502 | -mRNA | ||
| 503 | -Peptide | ||
| 504 | -SNAI | ||
| 505 | -BM | ||
| 506 | -ATPase | ||
| 507 | -AKT | ||
| 508 | -Fibroblastic | ||
| 509 | -Matriptase | ||
| 510 | -Sub | ||
| 511 | -Sustained | ||
| 512 | -Pleiotropic | ||
| 513 | -New | ||
| 514 | -Regulator | ||
| 515 | -Receptor | ||
| 516 | -Therapeutic | ||
| 517 | -Vimentin | ||
| 518 | -IGF | ||
| 519 | -Cells | ||
| 520 | -LIGHT | ||
| 521 | -Production | ||
| 522 | -D2 | ||
| 523 | -Dehydroepiandrosterone | ||
| 524 | -Lin28B | ||
| 525 | -Antifibrotic | ||
| 526 | -Raised | ||
| 527 | -Proliferation | ||
| 528 | -Dependent | ||
| 529 | -COL1 | ||
| 530 | -Lysocardiolipin | ||
| 531 | -Epithelium | ||
| 532 | -STAT3 | ||
| 533 | -Prevents | ||
| 534 | -Th1 | ||
| 535 | -NF | ||
| 536 | -CCN5 | ||
| 537 | -Snail | ||
| 538 | -Myogenic | ||
| 539 | -CD4 | ||
| 540 | -Akt | ||
| 541 | -TGFb1 | ||
| 542 | -Accelerated | ||
| 543 | -PDGF | ||
| 544 | -Intratracheal | ||
| 545 | -TGFB1 | ||
| 546 | -Cysteine | ||
| 547 | -Oxidant | ||
| 548 | -Effect | ||
| 549 | -Reprogramming | ||
| 550 | -IIP | ||
| 551 | -MS80 | ||
| 552 | -FOXF1 | ||
| 553 | -Promotes | ||
| 554 | -Assessment | ||
| 555 | -BLM | ||
| 556 | -CC16 | ||
| 557 | -BAL | ||
| 558 | -CD248 | ||
| 559 | -Ginsenoside | ||
| 560 | -Secreted | ||
| 561 | -Association | ||
| 562 | -IQ | ||
| 563 | -mTORC2 | ||
| 564 | -Established | ||
| 565 | -The | ||
| 566 | -Combined | ||
| 567 | -Jun | ||
| 568 | -UIP | ||
| 569 | -Sulf2 | ||
| 570 | -Thalidomide | ||
| 571 | -Bioenergetics | ||
| 572 | -TNF | ||
| 573 | -CCN2 | ||
| 574 | -NEU1 | ||
| 575 | -Attenuates | ||
| 576 | -HMGA2 | ||
| 577 | -Group | ||
| 578 | -Conversion | ||
| 579 | -Predisposition | ||
| 580 | -Transglutaminase | ||
| 581 | -Pathway | ||
| 582 | -Reviews | ||
| 583 | -Treg | ||
| 584 | -DDR2 | ||
| 585 | -Autophagy | ||
| 586 | -Hyper | ||
| 587 | -Bile | ||
| 588 | -Sunitinib | ||
| 589 | -Stiffening | ||
| 590 | -Signal | ||
| 591 | -Resolution | ||
| 592 | -De | ||
| 593 | -Type | ||
| 594 | -Factor | ||
| 595 | -Smad2 | ||
| 596 | -Single | ||
| 597 | -PPAR | ||
| 598 | -WNT5A | ||
| 599 | -Novo | ||
| 600 | -An | ||
| 601 | -EGFR | ||
| 602 | -Cub | ||
| 603 | -GLI | ||
| 604 | -HSP47 | ||
| 605 | -Early | ||
| 606 | -ERK1 | ||
| 607 | -TGFbeta | ||
| 608 | -Deficiency | ||
| 609 | -hydroxytryptamine2A | ||
| 610 | -BAX | ||
| 611 | -Inhibitory | ||
| 612 | -Integrin | ||
| 613 | -Suppression | ||
| 614 | -Shikonin | ||
| 615 | -SMAD3 | ||
| 616 | -Effects | ||
| 617 | -Metformin | ||
| 618 | -F1 | ||
| 619 | -MAPK | ||
| 620 | -Modulation | ||
| 621 | -Bleomycin | ||
| 622 | -Injury | ||
| 623 | -Elevated | ||
| 624 | -Cellular | ||
| 625 | -Radioligand | ||
| 626 | -Citrus | ||
| 627 | -TIAM1 | ||
| 628 | -Subjects | ||
| 629 | -Lung | ||
| 630 | -ARPC2 | ||
| 631 | -H19 | ||
| 632 | -EZH2 | ||
| 633 | -Pathways | ||
| 634 | -Is | ||
| 635 | -Microarray | ||
| 636 | -Fas | ||
| 637 | -CCN1 | ||
| 638 | -Ac | ||
| 639 | -miRNAs | ||
| 640 | -Myofibroblasts | ||
| 641 | -FFPE | ||
| 642 | -Inhibitor | ||
| 643 | -During | ||
| 644 | -Matrix | ||
| 645 | -Nrf2 | ||
| 646 | -Immunomodulation | ||
| 647 | -C5aR | ||
| 648 | -Gremlin | ||
| 649 | -High | ||
| 650 | -Concentration | ||
| 651 | -Evaluation | ||
| 652 | -Roles | ||
| 653 | -Number | ||
| 654 | -Bone | ||
| 655 | -ACLP | ||
| 656 | -Hypertension | ||
| 657 | -Lipogenic | ||
| 658 | -Uncoupling | ||
| 659 | -Signaling | ||
| 660 | -Lrp5 | ||
| 661 | -Berberine | ||
| 662 | -A4 | ||
| 663 | -CD11c | ||
| 664 | -miR | ||
| 665 | -Chop | ||
| 666 | -Galectin | ||
| 667 | -Alveolar | ||
| 668 | -Transition | ||
| 669 | -Plasma | ||
| 670 | -Impacts | ||
| 671 | -Smad4 | ||
| 672 | -Its | ||
| 673 | -Pathogenesis | ||
| 674 | -Inappropriate | ||
| 675 | -Investigation | ||
| 676 | -Beta | ||
| 677 | -Ca | ||
| 678 | -ERK | ||
| 679 | -Deregulation | ||
| 680 | -MSCs | ||
| 681 | -PTEN | ||
| 682 | -Lipoxin | ||
| 683 | -Nitric | ||
| 684 | -C1q | ||
| 685 | -KCa3 | ||
| 686 | -kappaB | ||
| 687 | -Involvement | ||
| 688 | -MCP | ||
| 689 | -Pleural | ||
| 690 | -EMMPRIN | ||
| 691 | -Smooth | ||
| 692 | -Synthesis | ||
| 693 | -Blockade | ||
| 694 | -Compared | ||
| 695 | -Transgelin |
| ... | @@ -4,4 +4,4 @@ grep -E "\|t\|" title-sentences.txt | perl -ne 'if(/(\d+\|t\|)(.*)/){print "$2\n | ... | @@ -4,4 +4,4 @@ grep -E "\|t\|" title-sentences.txt | perl -ne 'if(/(\d+\|t\|)(.*)/){print "$2\n |
| 4 | 4 | ||
| 5 | # Run wisse | 5 | # Run wisse |
| 6 | 6 | ||
| 7 | -python3.4 wisse_example.py --input ../corpora/abstracts-titles.txt --idfmodel local --embedmodel /export/space1/users/compu2/bionlp/word-embeddings/w2v/almac/ignacio/data/word2vec/indexed_w2v_En_vector_space_H300 --localw binary --output ../embeddings/abstracts-titles.vec --format wisse & | 7 | +python3.4 wisse_example.py --input ../corpora/articles-titles.txt --idfmodel local --embedmodel /export/space1/users/compu2/bionlp/word-embeddings/w2v/almac/ignacio/data/word2vec/indexed_w2v_En_vector_space_H300 --localw binary --output ../embeddings/articles-titles.vec --format wisse & | ... | ... |
-
Please register or login to post a comment